2022
A Multicenter Study of 2-year Outcomes Following Hyperthermia Therapy with Mitomycin C in Treating Non-Muscle Invasive Bladder Cancer: HIVEC-E
Tan W, Bello A, Alvarez C, Guerrero-Ramos F, González-Padilla D, Nzeh C, de la Morena J, de Torres I, Hendricksen K, Goizueta F, Del Álamo J, Chiancone F, Fedelini P, Poggio M, Porpiglia F, Rodríguez V, Torres J, Wilby D, Robinson R, Sousa-Escandón A, Mata J, Moreno J, Molina F, Semino M, Stemberger A, Escudero J, Redorta J, Tan W. A Multicenter Study of 2-year Outcomes Following Hyperthermia Therapy with Mitomycin C in Treating Non-Muscle Invasive Bladder Cancer: HIVEC-E. Bladder Cancer 2022, 8: 379-393. PMID: 38994184, PMCID: PMC11181696, DOI: 10.3233/blc-220026.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerTransurethral resection of bladder tumorRecurrence-free survivalProgression-free survivalInvasive bladder cancerMitomycin CBCG-naiveBladder cancerAdverse eventsTreated with intravesical bacillus Calmette-GuerinTreatment of non-muscle invasive bladder cancerIntravesical bacillus Calmette-GuerinResection of bladder tumorTreating non-muscle invasive bladder cancerFavorable adverse event profileAdverse event profileBacillus Calmette-GuerinMinor adverse eventsMulti-institutional studyBCG failurePapillary diseaseTransurethral resectionBladder tumorsConsecutive patientsMedian age
2021
1459 Intravesical Chemohyperthermia Versus Bacillus Calmette-Guerin Instillation for Intermediate- And High-Risk Non-Muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis
Zhao H, Chan V, Castellani D, Chan E, Ong W, Peng Q, Moschini M, Krajewski W, Pradere B, Ng C, Enikeev D, Vasdev N, Ekin G, Sousa A, Leon J, Guerrero-Ramos F, Tan W, Kelly J, Shariat S, Witjes J, Teoh J. 1459 Intravesical Chemohyperthermia Versus Bacillus Calmette-Guerin Instillation for Intermediate- And High-Risk Non-Muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. British Journal Of Surgery 2021, 108: znab259.955. DOI: 10.1093/bjs/znab259.955.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerHigh-risk non-muscle invasive bladder cancerRecurrence-free survivalProgression-free survivalInvasive bladder cancerCarcinoma in situChemo-hyperthermiaAdverse eventsChemotherapy instillationSafety profileBladder cancerBCG groupBCG maintenance therapyTrans-urethral resectionMeta-analysisMonths recurrence rateSystematic reviewComprehensive literature searchQuality of evidenceBCG failureBCG shortageMaintenance therapyOncological outcomesRandomised controlled trialsRecurrence rate
2020
Quality of surgical care can impact survival in patients with bladder cancer after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium
Ahmed Y, Hussein A, May P, Ahmad B, Khan A, Benkowski J, Durrani A, Khan S, Kozlowski J, Saar M, Wijburg C, Richstone L, Wagner A, Yuh B, Redorta J, Dasgupta P, Khan M, Menon M, Peabody J, Hosseini A, Gaboardi F, Pini G, Schanne F, Mottrie A, Rha K, Hemal A, Stockle M, Kelly J, Tan W, Maatman T, Poulakis V, Kaouk J, Canda A, Balbay M, Wiklund P, Guru K. Quality of surgical care can impact survival in patients with bladder cancer after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. African Journal Of Urology 2020, 26: 22. DOI: 10.1186/s12301-020-00031-y.Peer-Reviewed Original ResearchOrgan-confined diseaseLocally advanced diseaseDisease-specific survivalRecurrence-free survivalRobot-assisted radical cystectomyOverall survivalQuality of surgical careRadical cystectomyBladder cancerSurgical carePositive lymph node statusMultivariate stepwise logistic regressionImpact of surgical factorsPositive surgical marginsLymph node statusKaplan-Meier methodPredictors of survivalStepwise logistic regressionCompare surgical performanceOS ratesSurgical marginsPT stageAdjuvant chemotherapyNode statusAdvanced disease
2018
Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment
Wong Y, Joshi K, Khetrapal P, Ismail M, Reading J, Sunderland M, Georgiou A, Furness A, Aissa A, Ghorani E, Oakes T, Uddin I, Tan W, Feber A, McGovern U, Swanton C, Freeman A, Marafioti T, Briggs T, Kelly J, Powles T, Peggs K, Chain B, Linch M, Quezada S. Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment. Journal Of Experimental Medicine 2018, 215: 2748-2759. PMID: 30257862, PMCID: PMC6219732, DOI: 10.1084/jem.20181003.Peer-Reviewed Original ResearchConceptsMuscle invasive bladder cancerImmune tumor microenvironmentTumor microenvironmentImmuno-oncologyT cellsBladder cancerExpression of PD-1Response to checkpoint blockadeShorter recurrence-free survivalT cell receptor repertoireSource of T cellsEffector CD8<sup>+</sup>Recurrence-free survivalInvasive bladder cancerRegulatory T cellsTumor immune microenvironmentCD4<sup>+</sup> cellsFraction of patientsImmunotherapy combinationsCheckpoint blockadePD-1Cancer immunotherapyCD8<sup>+</sup>Immune microenvironmentPrognostic value
2015
Robot‐assisted intracorporeal pyramid neobladder
Tan W, Sridhar A, Goldstraw M, Zacharakis E, Nathan S, Hines J, Cathcart P, Briggs T, Kelly J. Robot‐assisted intracorporeal pyramid neobladder. BJU International 2015, 116: 771-779. PMID: 26033321, DOI: 10.1111/bju.13189.Peer-Reviewed Original ResearchConceptsRobot-assisted radical cystectomyMuscle-invasive bladder cancerUrinary tract infectionPostoperative complicationsFunctional outcomesMedian estimated blood lossNight time continenceBilateral pelvic lymphadenectomyEstimated blood lossMedian hospital stayRecurrence-free survivalUpper tract imagingMedian follow-upLate postoperative complicationsEarly postoperative complicationsPort-site herniaUretero-ileal strictureVitamin B12 deficiencyBlocked stentsNeobladder stonePelvic lymphadenectomyOncological outcomesRadical cystectomyOverall survivalBlood loss